Navigation Links
Hookworms in MS trial
Date:3/3/2009

Scientists from The University of Nottingham will study the potential health benefits of parasitic worms as part of a study investigating treatments for people with the autoimmune condition multiple sclerosis (MS).

It is thought that hookworms may play a role in damping down the immune system, which is overactive in people with MS, the most disabling neurological condition in young adults.

The 400,000, three-year project funded by the MS Society, aims to determine whether infection with a small and harmless number of the worms can lead to an improvement on the severity of MS over a 12 month period.

If the trial is successful, the worms have the potential to provide a simple, cheap, natural and controllable treatment for MS.

The WIRMS (Worms for Immune Regulation in MS) study is led by Professor Cris Constantinescu and Professor David Pritchard and is a randomised, placebo controlled, phase 2 study in people with relapsing remitting MS and will be carried out at multiple centres up and down the country.

The 25 worms are microscopic and are introduced painlessly through a patch in the arm. They are then flushed out after nine months.

Professor Constantinescu, said: "People are really interested in this form of potential therapy because it's a natural treatment. It's been tested for safety and we now need to study the potential benefits and any side effects."

Jayne Spink, Director of Research at the MS Society said: "It sounds like science fiction, but it has been shown in a previous small study that people with MS who also had gut parasite infections had fewer relapses.

"Over time, parasitic worms have evolved to be able to survive an immune system attack and have been linked to a reduction in the severity of the symptoms of MS, which can be debilitating.

"If the theories can be shown to be accurate, using hookworms as a future treatment option may prove to be science fact."

MS affects more than 85,000 people in the UK and several million worldwide. Symptoms range from loss of sight and mobility, fatigue, depression and cognitive problems that often come on as attack - or relapses. There is no cure and few effective treatments.

Dorothy Sutton, 58, from Awsworth, has lived with MS for 32 years and is a Helpline volunteer for the MS Society. She said that although the treatment sounded unusual, anything that could potentially to help alleviate the symptoms of MS is a positive step.

"We have to explore every avenue of research to find treatments for MS. As long as it's safe and effective in helping the horrible symptoms, I don't think people mind where it comes from."

The Division of Clinical Neurology at The University of Nottingham's Medical School is a strong research-led unit which draws heavily on its close relationship with people with MS to inform its work.

Led by Professor Cris Constantinescu, the department features two academic and one NHS Neurology Consultants that are affiliated with the Neuroscience Directorate of Nottingham University Hospitals (NUH) NHS Trusts.


'/>"/>

Contact: Professor Cris Constantinescu
cris.constantinescu@nottingham.ac.uk
44-011-584-66597
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
2. CANTAM first African Network of Excellence for clinical trials
3. Stemedica Advances its Certification to Become a Licensed Manufacturer of Adult Stem Cells for U.S. Based Clinical Trials
4. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
5. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
6. Laser Therapy Disappoints in Stroke Trial
7. Landmark Trial Provides Vital Information for Cardiac Disease Treatment
8. Many Clinical Trials Moving Overseas
9. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
10. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
11. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: